In a new FDA-approved clinical trial, a patient with COVID-19 and lung failure is the first to be treated with mesenchymal stem cells (MSCs) at the University of Minnesota. In determining its safety and efficacy, this clinical trial—intended for some of the socket patients with COVID-19—hopes to see a halt to the intense inflammatory response of the body referred to as a “cytokine storm.”
Led by David Ingbar, MD, this study was developed by the team of researchers at the University of Minnesota and will include other academic centers across the U.S. According to a report by Message Media, “The multisite study is open now at M Health Fairview UMMC and Bethesda Hospital, which was previously converted into the state’s first dedicated COVID-19 care facility.”
The MSCs used in this study were produced and manufactured at the U of M’s Molecular and Cellular Therapeutics (MCT) center, which offers full-service development and manufacturing of cell- and tissue-based products, monoclonal antibodies and other therapeutic proteins, as well as active pharmaceutical ingredients for use in Phase I, II or III clinical trials.
As a side note, MSCs have been used success...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).